

Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma

Jason Konner · Rachel N. Grisham · Jae Park ·
Owen A. O'Connor · Gillian Cropp · Robert Johnson ·
Alison L. Hannah · Martee L. Hensley · Paul Sabbatini ·
Svetlana Mironov · Samuel Danishefsky ·
David Hyman · David R. Spriggs · Jakob Dupont ·
Carol Aghajanian

Published online: 3 January 2012
© Springer Science+Business Media, LLC 2011

Erratum to: Invest New Drugs DOI 10.1007/s10637-011-9765-7

The surname of the author Svetlana Mironov, MD, was misspelled. The correct author's surname should be "Mironov," not "Miranov".

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-011-9765-7>.

J. Konner (✉) · R. N. Grisham · J. Park · M. L. Hensley ·
P. Sabbatini · D. Hyman · D. R. Spriggs · C. Aghajanian
Gynecologic Medical Oncology Service, Department of Medicine,
Memorial Sloan-Kettering Cancer Center,
1275 York Avenue,
New York, NY 10021, USA
e-mail: konnerj@mskcc.org

O. A. O'Connor
New York University Cancer Institute,
New York, NY, USA

G. Cropp · A. L. Hannah
Nereus Pharmaceuticals, Inc.,
San Diego, CA, USA

R. Johnson
Aeolian Biomed,
Lafayette, CA, USA

S. Mironov
Department of Radiology,
Memorial Sloan-Kettering Cancer Center,
New York, NY, USA

S. Danishefsky
Department of Molecular Pharmacology and Chemistry,
Memorial Sloan-Kettering Cancer Center,
New York, NY, USA

J. Dupont
Genentech, Inc.,
1 DNA Way,
South San Francisco, CA, USA